/PRNewswire/ As per Zion Market Research study, The global basal cell carcinoma treatment market had total revenues of roughly USD 5.53 billion in 2021 and.
Surgical treatment dominates with the highest revenue amongst all treatment options in the basal cell carcinoma treatment market, with a projected value of US$ 6 billion by the end of 2025. Mohs surgery is found to be an effective treatment for basal cell carcinoma (BCC), whereas, surgical excision accounts for the.
Surgical treatment dominates with the highest revenue amongst all treatment options in the basal cell carcinoma treatment market, with a projected value of US$ 6 billion by the end of 2025. Mohs surgery is found to be an effective treatment for basal cell carcinoma (BCC), whereas, surgical excision accounts for the.
Basal Cell Carcinoma Treatment Market Forecast and Trends Analysis Research Report 2021 to 2031 pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Search jobs 04-Aug-2021 Non-Surgical Basal Cell Carcinoma Treatment Is Predicted to Grow at a Staggering CAGR of 9% by 2025
Surgical treatment dominates with the highest revenue amongst all treatment options in the basal cell carcinoma treatment market, with a projected value of US$ 6 billion by the end of 2025. Mohs surgery is found to be an effective treatment for basal cell carcinoma (BCC), whereas, surgical excision accounts for the highest revenue amongst surgical treatment types.
Companies in the basal cell carcinoma treatment market are introducing improved formulations of molecular targeting agents approved by the FDA. For instance, vismodegib and sonidegib are two oral inhibitors approved by the FDA for the treatment of advanced BCC. A study published by the department of dermatology at the Keio University School of Medicine, Japan, stated that, antifungal drugs help to significantly reduce tumor size in BCC patients. Phar